| Psoriasis vulgaris
Otezla vs Taltz
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Otezla vs Taltz with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTaltz has a higher rate of injection site reactions vs Otezla based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Taltz but not Otezla, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Otezla
Taltz
At A Glance
Oral
Once or twice daily
PDE4 inhibitor
SC injection
Every 4 weeks (maintenance)
IL-17A antagonist
Indications
- Arthritis, Psoriatic
- Psoriasis vulgaris
- Behcet Syndrome
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Non-Radiographic Axial Spondyloarthritis
Dosing
Arthritis, Psoriatic, Psoriasis vulgaris, Behcet Syndrome Adults: OTEZLA 30 mg twice daily or OTEZLA XR 75 mg once daily orally after 5-day titration starting at 10 mg; reduce to 30 mg once daily in severe renal impairment (OTEZLA XR not recommended in severe renal impairment).
Arthritis, Psoriatic, Psoriasis vulgaris (pediatric >=6 years) Weighing >=50 kg: OTEZLA 30 mg twice daily or OTEZLA XR 75 mg once daily orally after weight-based titration; weighing 20 to <50 kg: OTEZLA 20 mg twice daily orally; reduce to once daily dosing in severe renal impairment.
Psoriasis vulgaris 160 mg SC at Week 0, then 80 mg at Weeks 2, 4, 6, 8, 10, 12, followed by 80 mg every 4 weeks.
Arthritis, Psoriatic 160 mg SC at Week 0, followed by 80 mg every 4 weeks.
Ankylosing spondylitis, Non-Radiographic Axial Spondyloarthritis 160 mg SC at Week 0, followed by 80 mg every 4 weeks.
Contraindications
- Known hypersensitivity to apremilast or to any of the excipients in the formulation
- Previous serious hypersensitivity reaction to ixekizumab or to any of the excipients
Adverse Reactions
Most common (>=2%) Diarrhea, nausea, headache, upper respiratory tract infection, vomiting, abdominal pain upper, nasopharyngitis
Serious Hypersensitivity, depression, weight decrease, severe worsening of psoriasis (rebound)
Most common (>=1%) Injection site reactions, upper respiratory tract infections, nausea, tinea infections.
Serious Serious infections, hypersensitivity reactions including anaphylaxis, inflammatory bowel disease.
Pharmacology
Apremilast is an oral small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP); PDE4 inhibition increases intracellular cAMP levels and reduces pro-inflammatory cytokines including IL-17, IL-22, and TNF-alpha in blood and skin.
Humanized IgG4 monoclonal antibody that selectively binds to interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Otezla
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (9/12)
Taltz
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Otezla
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (2/8) · Qty limit (8/8)
Taltz
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Otezla
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Taltz
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAmgen Safety Net Foundation: Otezla
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$25/momo
Taltz Savings Card - Non-covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.